Q-omics provides the consensus-scored WASL-DT profile across patient tissues and cancer cell-line models. WASL-DT expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WASL-DT is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, WASL-DT RNA expression shows 19,346 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where WASL-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WASL-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WASL-DT survival associations across molecular data types. WASL-DT RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WASL-DT RNA expression–survival associations across cancer types. High WASL-DT expression shows favorable associations in KIRC, OV, BRCA, UCS, SARC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WASL-DT RNA expression.
This table summarizes WASL-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for WASL-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WASL-DT shows lower tumor expression in THCA, COAD, KICH, READ, LUAD and UCEC. The THCA box plot shows higher WASL-DT RNA expression in normal versus tumor tissue (log2 FC = −0.877, t-test p < 0.001).
This table shows molecular features associated with WASL-DT in patient tissues and cancer cell lines. In patient samples, WASL-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
